vs
Apellis Pharmaceuticals, Inc.（APLS）与DONEGAL GROUP INC（DGICA）财务数据对比。点击上方公司名可切换其他公司
DONEGAL GROUP INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.2倍（$239.8M vs $199.9M），DONEGAL GROUP INC净利率更高（7.2% vs -29.5%，领先36.7%），DONEGAL GROUP INC同比增速更快（-4.1% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -0.3%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
多尼戈尔集团是一家美国地区性保险控股企业，提供个人及商业财产和意外伤害保险产品，主要服务美国中大西洋、中西部及南部地区客户，为个人、家庭及中小型企业提供定制化保障方案。
APLS vs DGICA — 直观对比
营收规模更大
DGICA
是对方的1.2倍
$199.9M
营收增速更快
DGICA
高出1.9%
-5.9%
净利率更高
DGICA
高出36.7%
-29.5%
两年增速更快
APLS
近两年复合增速
-0.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $239.8M |
| 净利润 | $-59.0M | $17.2M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 8.7% |
| 净利率 | -29.5% | 7.2% |
| 营收同比 | -5.9% | -4.1% |
| 净利润同比 | -62.2% | -28.4% |
| 每股收益（稀释后） | $-0.40 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSDGICA
| Q4 25 | $199.9M | $239.8M | ||
| Q3 25 | $458.6M | $245.9M | ||
| Q2 25 | $178.5M | $247.1M | ||
| Q1 25 | $166.8M | $245.2M | ||
| Q4 24 | $212.5M | $250.0M | ||
| Q3 24 | $196.8M | $251.7M | ||
| Q2 24 | $199.7M | $246.8M | ||
| Q1 24 | $172.3M | $241.1M |
净利润APLSDGICA
| Q4 25 | $-59.0M | $17.2M | ||
| Q3 25 | $215.7M | $20.1M | ||
| Q2 25 | $-42.2M | $16.9M | ||
| Q1 25 | $-92.2M | $25.2M | ||
| Q4 24 | $-36.4M | $24.0M | ||
| Q3 24 | $-57.4M | $16.8M | ||
| Q2 24 | $-37.7M | $4.2M | ||
| Q1 24 | $-66.4M | $6.0M |
营业利润率APLSDGICA
| Q4 25 | -25.6% | 8.7% | ||
| Q3 25 | 48.7% | 10.2% | ||
| Q2 25 | -18.6% | 8.3% | ||
| Q1 25 | -50.0% | 12.7% | ||
| Q4 24 | -12.3% | 11.9% | ||
| Q3 24 | -24.0% | 8.1% | ||
| Q2 24 | -14.7% | 2.0% | ||
| Q1 24 | -36.0% | 3.0% |
净利率APLSDGICA
| Q4 25 | -29.5% | 7.2% | ||
| Q3 25 | 47.0% | 8.2% | ||
| Q2 25 | -23.6% | 6.8% | ||
| Q1 25 | -55.3% | 10.3% | ||
| Q4 24 | -17.1% | 9.6% | ||
| Q3 24 | -29.2% | 6.7% | ||
| Q2 24 | -18.9% | 1.7% | ||
| Q1 24 | -38.5% | 2.5% |
每股收益（稀释后）APLSDGICA
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | — | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | — | ||
| Q3 24 | $-0.46 | — | ||
| Q2 24 | $-0.30 | — | ||
| Q1 24 | $-0.54 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $640.4M |
| 总资产 | $1.1B | $2.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSDGICA
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — | ||
| Q1 24 | $325.9M | — |
总债务APLSDGICA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSDGICA
| Q4 25 | $370.1M | $640.4M | ||
| Q3 25 | $401.2M | $627.4M | ||
| Q2 25 | $156.3M | $605.7M | ||
| Q1 25 | $164.2M | $584.7M | ||
| Q4 24 | $228.5M | $545.8M | ||
| Q3 24 | $237.1M | $513.4M | ||
| Q2 24 | $264.3M | $484.1M | ||
| Q1 24 | $266.7M | $485.1M |
总资产APLSDGICA
| Q4 25 | $1.1B | $2.4B | ||
| Q3 25 | $1.1B | $2.4B | ||
| Q2 25 | $821.4M | $2.4B | ||
| Q1 25 | $807.3M | $2.4B | ||
| Q4 24 | $885.1M | $2.3B | ||
| Q3 24 | $901.9M | $2.3B | ||
| Q2 24 | $904.5M | $2.3B | ||
| Q1 24 | $831.9M | $2.3B |
负债/权益比APLSDGICA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $70.2M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | 4.08× |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSDGICA
| Q4 25 | $-14.2M | $70.2M | ||
| Q3 25 | $108.5M | $22.4M | ||
| Q2 25 | $4.4M | $12.1M | ||
| Q1 25 | $-53.4M | $25.7M | ||
| Q4 24 | $19.4M | $67.4M | ||
| Q3 24 | $34.1M | $12.7M | ||
| Q2 24 | $-8.3M | $21.7M | ||
| Q1 24 | $-133.0M | $4.8M |
自由现金流APLSDGICA
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | — |
自由现金流率APLSDGICA
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | — |
资本支出强度APLSDGICA
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
现金转化率APLSDGICA
| Q4 25 | — | 4.08× | ||
| Q3 25 | 0.50× | 1.11× | ||
| Q2 25 | — | 0.72× | ||
| Q1 25 | — | 1.02× | ||
| Q4 24 | — | 2.81× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 5.22× | ||
| Q1 24 | — | 0.81× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
DGICA
| Commercial Lines Segment | $140.8M | 59% |
| Personal Lines Segment | $86.0M | 36% |
| Investments Function Segment | $12.4M | 5% |
